Integrating resistance functions to predict response to induction chemotherapy in de novo acute myeloid leukemia.
Yu-Chiao ChiuTzu-Hung HsiaoJia-Rong TsaiLi-Ju WangTzu-Chieh HoShih-Lan HsuChieh-Lin Jerry TengPublished in: European journal of haematology (2019)
Myc, OXPHOS, mTOR, and stemness were responsive for chemoresistance in AML. Treatments other than the "7 + 3" regimen need to be considered for de novo AML patients predicted to be refractory to the "7 + 3" regimen.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- ejection fraction
- stem cells
- chronic kidney disease
- cell proliferation
- epithelial mesenchymal transition
- peritoneal dialysis
- prognostic factors
- transcription factor
- cancer therapy
- drug delivery
- signaling pathway
- radiation therapy
- patient reported